

Budgetary overview

Portfolio: 7 candidates (criteria: early supply, different technologies)

1	AstraZeneca	Non-replicating viral vector
2	Sanofi / GSK	Proteine subunit
3	Janssen Pharmaceutical	Non-replicating viral vector
4	Curevac	mRNA
5	Moderna	mRNA
6	BioNTech/ Pfizer	mRNA
7	Novavax	Proteine subunit

Additional Budget on top of ESI needed with a broad portfolio

	Upfront payment	Volume
BioNTech/Pfizer	€ 5.1.2b	200 mio doses, with € 5.1.2b from ESI
Novavax	€ 5.1.2b	100 mio doses with 100 mio doses
Total	€	

